AML-251 Overall Survival (OS) With Intensive Chemotherapy (IC) vs Non-IC in Patients With Newly Diagnosed (ND) AML from the Connect® Myeloid Disease Registry Ineligible for Randomized Clinical Trials (RCT)

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2022-10, Vol.22, p.S229-S230
Main Authors: Erba, Harry P., Pollyea, Daniel A., Sekeres, Mikkael A., Garcia-Manero, Guillermo, Seiter, Karen, DeGutis, Irene S., Kiselev, Pavel, McBride, Ali, Yu, Edward, Roboz, Gail J.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2152-2650
DOI:10.1016/S2152-2650(22)01254-X